ZA928373B - 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives - Google Patents
1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivativesInfo
- Publication number
- ZA928373B ZA928373B ZA928373A ZA928373A ZA928373B ZA 928373 B ZA928373 B ZA 928373B ZA 928373 A ZA928373 A ZA 928373A ZA 928373 A ZA928373 A ZA 928373A ZA 928373 B ZA928373 B ZA 928373B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- compounds
- dihydro
- derivatives
- halo
- Prior art date
Links
- BINWKEIURMBREF-UHFFFAOYSA-N 1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical class C1=CC=C2N=C(NC(=O)N3)C3=CC2=C1 BINWKEIURMBREF-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78495591A | 1991-10-30 | 1991-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA928373B true ZA928373B (en) | 1994-04-29 |
Family
ID=25134048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA928373A ZA928373B (en) | 1991-10-30 | 1992-10-29 | 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives |
Country Status (24)
Country | Link |
---|---|
US (3) | US5521187A (xx) |
EP (2) | EP0541153A1 (xx) |
JP (1) | JP3488922B2 (xx) |
KR (1) | KR100251895B1 (xx) |
CN (1) | CN1041726C (xx) |
AT (1) | ATE131479T1 (xx) |
AU (1) | AU660337B2 (xx) |
CA (1) | CA2121230C (xx) |
DE (1) | DE69206820T2 (xx) |
DK (1) | DK0610372T3 (xx) |
ES (1) | ES2083773T3 (xx) |
FI (1) | FI105548B (xx) |
GR (1) | GR3018909T3 (xx) |
HU (1) | HU220608B1 (xx) |
IL (1) | IL103570A (xx) |
MX (1) | MX9206258A (xx) |
NO (1) | NO300976B1 (xx) |
NZ (1) | NZ244779A (xx) |
PH (1) | PH31245A (xx) |
PL (1) | PL170749B1 (xx) |
RU (1) | RU2127273C1 (xx) |
TW (1) | TW249234B (xx) |
WO (1) | WO1993009118A1 (xx) |
ZA (1) | ZA928373B (xx) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
US5502177A (en) * | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5703827A (en) * | 1996-02-29 | 1997-12-30 | Monolithic System Technology, Inc. | Method and structure for generating a boosted word line voltage and a back bias voltage for a memory array |
US6007992A (en) * | 1997-11-10 | 1999-12-28 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US6028183A (en) * | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
IL155163A0 (en) * | 2000-10-02 | 2003-10-31 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US20040146561A1 (en) | 2001-05-23 | 2004-07-29 | Naoki Sakurai | Compositions for promoting healing of bone fracture |
MXPA03010672A (es) | 2001-05-23 | 2004-03-02 | Tanabe Seiyaku Co | Composicion para el tratamiento regenerativo de enfermedades del cartilago. |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
UA78548C2 (en) * | 2002-03-29 | 2007-04-10 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and use thereof as metabotropic ligands of glutamate receptor |
SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
AR045260A1 (es) | 2003-08-12 | 2005-10-19 | 3M Innovative Properties Co | Compuestos que contienen imidazo-oxima sustituidos |
RU2006105101A (ru) | 2003-08-27 | 2007-10-10 | 3М Инновейтив Пропертиз Компани (US) | Арилокси и арилалкиленокси замещенные имидазохинолины |
US20050054665A1 (en) | 2003-09-05 | 2005-03-10 | 3M Innovative Properties Company | Treatment for CD5+ B cell lymphoma |
BRPI0414856A (pt) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
JP2007511535A (ja) | 2003-11-14 | 2007-05-10 | スリーエム イノベイティブ プロパティズ カンパニー | ヒドロキシルアミン置換イミダゾ環化合物 |
AU2004291101A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
EP1687307B1 (en) | 2003-11-25 | 2016-01-06 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
EP1701955A1 (en) | 2003-12-29 | 2006-09-20 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
CA2551399A1 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
WO2005090316A1 (en) * | 2004-03-12 | 2005-09-29 | Wyeth | HYDANTOINS HAVING RNase MODULATORY ACTIVITY |
US8697873B2 (en) | 2004-03-24 | 2014-04-15 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
US8017779B2 (en) | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
WO2006038923A2 (en) | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
ES2392648T3 (es) | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado |
CA2592904C (en) | 2004-12-30 | 2015-04-07 | 3M Innovative Properties Company | Chiral fused [1,2]imidazo[4,5-c] ring compounds |
US9248127B2 (en) | 2005-02-04 | 2016-02-02 | 3M Innovative Properties Company | Aqueous gel formulations containing immune response modifiers |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7906506B2 (en) | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
EP1969929A1 (de) * | 2007-03-12 | 2008-09-17 | Bayer CropScience AG | Substituierte Phenylamidine und deren Verwendung als Fungizide |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
US9908840B2 (en) | 2012-10-02 | 2018-03-06 | California Institute Of Technology | Reactions of aromatic substrates with base-activated hydrosilanes-silylations and reductive cleavage |
WO2014055587A1 (en) * | 2012-10-02 | 2014-04-10 | California Institute Of Techonolgy | Transition-metal-free silylation of aromatic compounds |
WO2016022624A1 (en) | 2014-08-06 | 2016-02-11 | California Institute Of Technology | Silylation of aromatic heterocycles by earth abundant transition-metal-free catalysts |
WO2016036685A1 (en) | 2014-09-02 | 2016-03-10 | California Institute Of Technology | Base-catalyzed silylation of terminial alkyne c-h bonds |
US9556080B2 (en) | 2014-12-19 | 2017-01-31 | California Institute Of Technology | Silylation of aromatic heterocycles by disilanes using potassium alkoxide catalysts |
CN110441434A (zh) * | 2019-08-29 | 2019-11-12 | 重庆华邦胜凯制药有限公司 | Gc-ms分离测定对氨基水杨酸中相关杂质的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1602188A (en) * | 1977-12-01 | 1981-11-11 | Wellcome Found | Hydantoin derivatives |
JPS6021941B2 (ja) * | 1981-01-28 | 1985-05-30 | 株式会社村田製作所 | 圧電性磁器組成物 |
US4668686A (en) * | 1985-04-25 | 1987-05-26 | Bristol-Myers Company | Imidazoquinoline antithrombrogenic cardiotonic agents |
US4775674A (en) * | 1986-05-23 | 1988-10-04 | Bristol-Myers Company | Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors |
US4701459A (en) * | 1986-07-08 | 1987-10-20 | Bristol-Myers Company | 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation |
US5306822A (en) * | 1988-05-25 | 1994-04-26 | Warner-Lambert Company | Arylmethylenyl derivatives of oxazolidinone |
NZ234186A (en) * | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
CN1030196C (zh) * | 1989-07-07 | 1995-11-01 | 詹森药业有限公司 | 增强收缩力和舒张力的-二氢咪唑并喹唑啉酮衍生物的制备方法 |
US5043327A (en) * | 1989-07-18 | 1991-08-27 | Janssen Pharmaceutica N.V. | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use |
US4943573A (en) * | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
WO1991007177A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders |
PH31245A (en) * | 1991-10-30 | 1998-06-18 | Janssen Pharmaceutica Nv | 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives. |
-
1992
- 1992-10-13 PH PH45100A patent/PH31245A/en unknown
- 1992-10-16 NZ NZ244779A patent/NZ244779A/en unknown
- 1992-10-22 TW TW081108413A patent/TW249234B/zh active
- 1992-10-27 KR KR1019940701365A patent/KR100251895B1/ko not_active IP Right Cessation
- 1992-10-27 JP JP50815493A patent/JP3488922B2/ja not_active Expired - Lifetime
- 1992-10-27 ES ES92923030T patent/ES2083773T3/es not_active Expired - Lifetime
- 1992-10-27 EP EP92203295A patent/EP0541153A1/en active Pending
- 1992-10-27 WO PCT/EP1992/002496 patent/WO1993009118A1/en active IP Right Grant
- 1992-10-27 CA CA002121230A patent/CA2121230C/en not_active Expired - Lifetime
- 1992-10-27 EP EP92923030A patent/EP0610372B1/en not_active Expired - Lifetime
- 1992-10-27 AT AT92923030T patent/ATE131479T1/de not_active IP Right Cessation
- 1992-10-27 PL PL92303446A patent/PL170749B1/pl unknown
- 1992-10-27 AU AU29083/92A patent/AU660337B2/en not_active Expired
- 1992-10-27 RU RU94019971/04A patent/RU2127273C1/ru not_active IP Right Cessation
- 1992-10-27 DK DK92923030.8T patent/DK0610372T3/da active
- 1992-10-27 US US08/204,412 patent/US5521187A/en not_active Expired - Lifetime
- 1992-10-27 HU HU9401245A patent/HU220608B1/hu not_active IP Right Cessation
- 1992-10-27 DE DE69206820T patent/DE69206820T2/de not_active Expired - Lifetime
- 1992-10-28 IL IL10357092A patent/IL103570A/en not_active IP Right Cessation
- 1992-10-29 MX MX9206258A patent/MX9206258A/es unknown
- 1992-10-29 ZA ZA928373A patent/ZA928373B/xx unknown
- 1992-10-30 CN CN92112391A patent/CN1041726C/zh not_active Expired - Fee Related
-
1994
- 1994-04-25 NO NO941497A patent/NO300976B1/no not_active IP Right Cessation
- 1994-04-29 FI FI942010A patent/FI105548B/fi not_active IP Right Cessation
-
1995
- 1995-04-18 US US08/423,920 patent/US5541325A/en not_active Expired - Lifetime
- 1995-04-18 US US08/423,116 patent/US5516908A/en not_active Expired - Lifetime
-
1996
- 1996-02-07 GR GR960400315T patent/GR3018909T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA928373B (en) | 1,3-dihydro-2h-imidazo(4,5-b)quinolin-2-one derivatives | |
EP0395328A3 (en) | Penylpyrimidone derivates and their use as therapeutic agents | |
AU5024293A (en) | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation | |
NO173870C (no) | Analogifremgnagsmaate for fremstilling av terapeutisk aktive 3,5-dihydroimidazo(2,1-b)binazolin-2(1h)-on-derivater | |
IL157819A0 (en) | Triazaspiro [5.5] undecane dericatives and drugs containing the same as the active ingredient | |
IL91704A0 (en) | Imidazoline derivatives,their preparation and pharmaceutical compositions containing them | |
NO921413D0 (no) | Pyrazolopyridin-forbindelser og fremgangsmaate for fremstilling derav | |
NZ214156A (en) | Quindone derivatives and pharmaceutical compositions | |
IL110060A (en) | 5-Amino-8- methyl-7-pyrrolidinylquinoline 3-carboxylic acid derivatives their preparation and pharmaceutical compositions containing them | |
IL141992A0 (en) | 2,3-disubstituted pyridine derivative, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor | |
DK0451538T3 (da) | Anvendelse af pyridoindolderivater til behandling af iskæmiske lidelser | |
EP0668276A4 (en) | 2-ALCOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF. | |
FI894125A (fi) | Analogiamenetelmä terapeuttisesti käyttökelpoisen 3-piperidinyyli-indatsolin valmistamiseksi | |
AU657423B2 (en) | Novel piperidine derivatives and process for preparation thereof | |
GB8907306D0 (en) | New compositions of matter |